Journal of Clinical Oncology, Vol 16, 3295-3301, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms' tumor: a French Society of Pediatric Oncology study

F Pein, J Michon, D Valteau-Couanet, E Quintana, D Frappaz, JP Vannier, T Philip, C Bergeron, MC Baranzelli, A Thyss, JL Stephan, P Boutard, JC Gentet, JM Zucker, MF Tournade and O Hartmann
Pediatric Oncology Department, Institut Gustave Roussy, Villejuif, France. pein@igr.fr

PURPOSE: The three-drug combination of melphalan (M), etoposide (E), and carboplatin (C) followed by autologous stem-cell (ASC) rescue has been evaluated prospectively by the French Society of Pediatric Oncology (SFOP) in pediatric high-risk recurrent (HRR) Wilms' tumor (WT) patients with chemotherapy-responsive disease. PATIENTS AND METHODS: From October 1988 to October 1994, 29 patients with HRR WT were treated in nine SFOP centers. Two additional patients with stage IV anaplastic WT were consolidated in first complete response (CR) with the same regimen and have been studied separately. The regimen consisted of M 180 mg/m2 for 1 day, E 200 mg/m2/d for 5 days, and C at a daily targeted area under the concentration-time curve (AUC) of 4 mg x min/mL for 5 days. ASCs were reinfused 48 hours after M. RESULTS: Twelve of 28 assessable patients with HRR WT are still in continuous CR at a median of 48.5 months (range, 36 to 96) after consolidation. Disease-free survival (DFS) and overall survival (OS) estimated by the Kaplan-Meier method at 3 years were 50%+/-17% and 60%+/-18%, respectively. Sixteen patients relapsed at a median of 8.5 months (range, 3 to 53) after consolidation. Toxicity data are available in 31 grafted patients. Grade III and IV toxicities included hematologic side effects (n=31), hemorrhage (n=8), mucositis (n=24), diarrhea (n=12), renal disorders (n=8), and pneumonitis (n=3). CONCLUSION: The adverse prognostic factors (APF) used to select patients for this dose- intensive chemotherapy define children with very-poor-risk recurrent WT. Despite high treatment-related toxicity, about half of these patients remain disease-free at 3 years. Patient outcome is statistically better when high-dose chemotherapy (HDCT) is performed as early as the second CR or partial response (PR). Novel therapeutic approaches with innovative preparative regimens are warranted for the remaining high-risk patients.

This article has been cited by other articles:

				H. M. Lazarus, G. L. Phillips, R. H. Herzig, D. D. Hurd, S. N. Wolff, and G. P. Herzig High-Dose Melphalan and the Development of Hematopoietic Stem-Cell Transplantation: 25 Years Later J. Clin. Oncol., May 10, 2008; 26(14): 2240 - 2243. [Full Text] [PDF]

				M. L. Metzger, C. F. Stewart, B. B. Freeman III, C. A. Billups, F. A. Hoffer, J. Wu, M. J. Coppes, R. Grant, M. Chintagumpala, E. A. Mullen, et al. Topotecan Is Active Against Wilms' Tumor: Results of a Multi-Institutional Phase II Study J. Clin. Oncol., July 20, 2007; 25(21): 3130 - 3136. [Abstract] [Full Text] [PDF]

				M. L. Metzger and J. S. Dome Current Therapy for Wilms' Tumor Oncologist, November 1, 2005; 10(10): 815 - 826. [Abstract] [Full Text] [PDF]

				A. D. Campbell, S. L. Cohn, M. Reynolds, R. Seshadri, E. Morgan, G. Geissler, A. Rademaker, M. Marymount, J. Kalapurakal, P. R. Haut, et al. Treatment of Relapsed Wilms' Tumor With High-Dose Therapy and Autologous Hematopoietic Stem-Cell Rescue: The Experience at Children's Memorial Hospital J. Clin. Oncol., July 15, 2004; 22(14): 2885 - 2890. [Abstract] [Full Text] [PDF]

				A. Weirich, R. Ludwig, N. Graf, U. Abel, I. Leuschner, G. M. Vujanic, O. Mehls, J. Boos, J. Beck, B. Royer-Pokora, et al. Survival in nephroblastoma treated according to the trial and study SIOP-9/GPOH with respect to relapse and morbidity Ann. Onc., May 1, 2004; 15(5): 808 - 820. [Abstract] [Full Text] [PDF]

				A. M. Abu-Ghosh, M. D. Krailo, S. C. Goldman, R. S. Slack, V. Davenport, E. Morris, J. H. Laver, G. H. Reaman, and M. S. Cairo Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms' tumor: a Children's Cancer Group report Ann. Onc., March 1, 2002; 13(3): 460 - 469. [Abstract] [Full Text] [PDF]